Sarah Teichmann
Directeur/Membre du Conseil chez 10X GENOMICS, INC.
Profil
Sarah A.
Teichmann is the founder of Transition Bio, Inc. She is currently working as the Director at 10X Genomics, Inc. She has an educational background from the University of Cambridge, where she completed her undergraduate, graduate, and doctorate degrees.
Postes actifs de Sarah Teichmann
| Sociétés | Poste | Début |
|---|---|---|
| 10X GENOMICS, INC. | Directeur/Membre du Conseil | 10/07/2024 |
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Fondateur | - |
Formation de Sarah Teichmann
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 10X GENOMICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |
